Related Experiment Video

Updated: Apr 25, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.3K

[Effect of PI3K/AKT pathway on cisplatin resistance in non-small cell lung cancer]

Yu Zhang1, Hongling Lu2, Gang Xu1

  • 1Departmen of Cardiothoracic Surgery, Affiliated Hospital of Zunyi Medical College, Zunyi 563099, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|August 19, 2014
PubMed

Insights

Aberrant activation of the phosphatidylinositol 3-kinase/AKT (PI3K/AKT) pathway drives non-small cell lung cancer progression and resistance to cisplatin chemotherapy. Understanding this link is crucial for improving treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
  • Cisplatin is a cornerstone first-line chemotherapy for NSCLC.
  • Acquired resistance to cisplatin significantly limits treatment success.

Purpose:

  • To review the current understanding of the phosphatidylinositol 3-kinase/AKT (PI3K/AKT) pathway.
  • To elucidate the role of PI3K/AKT pathway activation in the development of cisplatin resistance in NSCLC.
  • To highlight the implications for future therapeutic strategies.

Summary:

  • The PI3K/AKT pathway is frequently hyperactivated in NSCLC, promoting tumor cell proliferation, survival, and inhibiting apoptosis.
  • Sustained activation of the PI3K/AKT pathway is a key mechanism contributing to cisplatin resistance in NSCLC.
  • This review consolidates evidence linking PI3K/AKT signaling to chemotherapy resistance, providing a foundation for further research.

Impact:

  • Identifying PI3K/AKT as a critical mediator of cisplatin resistance offers potential therapeutic targets.
  • Strategies aimed at inhibiting the PI3K/AKT pathway may overcome or prevent resistance.
  • This research can guide the development of novel treatment combinations for NSCLC patients.

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K